Infectious diseases now · 2026
Combination of ertapenem and penicillin M or cefazolin in the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: multicenter case series.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bohard Louis, N'Guyen Yohan, Danneels Pierre, Martin-Blondel Guillaume, Zeggay Abdeljalil, Viguier Clément, Bouiller Kevin
Аннотация
BACKGROUND: Dual therapy (DT) combining penicillin M or cefazolin with ertapenem has been proposed as treatment of complicated Staphylococcus aureus bacteremia (SAB). We aimed to outline the relevant clinical characteristics and outcomes in real-life practice.
METHODS: We conducted a multicenter retrospective study involving SAB cases treated with DT in five French university hospitals between January 2022 and December 2024.
RESULTS: Thirty-five patients were included, all of them presenting with complicated SAB. Although DT was prescribed for persistent bacteremia, only 21 patients (60%) had positive blood cultures at DT initiation, related to blood culture incubation time. Median bacteremia duration after DT was two days (IQR 1-3). Two serious adverse events (5.7%), both encephalopathy, were reported. Seven patients (20%) died, five related to SAB or its management.
CONCLUSIONS: Due to blood culture delays, 40% of the patients had already cleared bacteremia before DT initiation. Further studies are needed to better define the role of this strategy and to identify the patients most likely to benefit.
METHODS: We conducted a multicenter retrospective study involving SAB cases treated with DT in five French university hospitals between January 2022 and December 2024.
RESULTS: Thirty-five patients were included, all of them presenting with complicated SAB. Although DT was prescribed for persistent bacteremia, only 21 patients (60%) had positive blood cultures at DT initiation, related to blood culture incubation time. Median bacteremia duration after DT was two days (IQR 1-3). Two serious adverse events (5.7%), both encephalopathy, were reported. Seven patients (20%) died, five related to SAB or its management.
CONCLUSIONS: Due to blood culture delays, 40% of the patients had already cleared bacteremia before DT initiation. Further studies are needed to better define the role of this strategy and to identify the patients most likely to benefit.